

# 1 **Monoallelic *CRMP1* gene variants cause neurodevelopmental disorder**

2 Ethiraj Ravindran,<sup>1-3§</sup> Nobuto Arashiki,<sup>4§</sup> Lena-Luise Becker,<sup>1-3#</sup> Kohtaro Takizawa,<sup>4#</sup>  
3 Jonathan Lévy,<sup>5,6</sup> Thomas Rambaud,<sup>6</sup> Konstantin L. Makridis,<sup>1-3</sup> Yoshio Goshima,<sup>7</sup> Na Li,<sup>8</sup>  
4 Maaïke Vreeburg,<sup>9</sup> Bénédicte Demeer,<sup>10, 11</sup> Achim Dickmanns,<sup>12</sup> Alexander P.A Stegmann,<sup>9</sup>  
5 Hao Hu,<sup>8\*</sup> Fumio Nakamura,<sup>4\*</sup> Angela M. Kaindl<sup>1-3\*</sup>

6

## 7 **Author affiliations:**

8 <sup>1</sup>Department of Pediatric Neurology, Charité–Universitätsmedizin Berlin, Berlin, 13353,  
9 Germany.

10 <sup>2</sup>Center for Chronically Sick Children, Charité–Universitätsmedizin Berlin, Berlin, 13353,  
11 Germany.

12 <sup>3</sup>Institute for Cell Biology and Neurobiology, Charité–Universitätsmedizin Berlin, Berlin,  
13 10117, Germany.

14 <sup>4</sup>Department of Biochemistry, Tokyo Women’s Medical University, Tokyo, Sinjuku-ku, 162-  
15 8666, Japan.

16 <sup>5</sup>Department of Genetics, APHP-Robert Debré University Hospital, Paris, 75019, France.

17 <sup>6</sup>Laboratoire de biologie médicale multisites Sequoia - FMG2025, Paris, 75014, France

18 <sup>7</sup>Department of Molecular Pharmacology and Neurobiology, Graduate School of Medicine,  
19 Yokohama City University, Yokohama, Kanazawa-ku, 236-0004, Japan.

20 <sup>8</sup>Laboratory of Medical Systems Biology, Guangzhou Women and Children's Medical Center,  
21 Guangzhou Medical University, 9 Jinsui Road, 510623, Guangzhou, China.

22 <sup>9</sup>Clinical Genetics, Maastricht University Medical Center, Maastricht, 6202, Netherlands.

23 <sup>10</sup> Center for Human Genetics, CLAD Nord de France, CHU Amiens-Picardie, Amiens,  
24 80054, France

25 <sup>11</sup>CHIMERE EA 7516, University Picardie Jules Verne, Amiens, France

26 <sup>12</sup>Department of Molecular Structural Biology, Institute for Microbiology and Genetics  
27 (GZMB), Georg-August-University Göttingen, Göttingen, 37077, Germany

28

29 \*, §, # These authors contributed equally to this work.

30

31 **Corresponding authors:**

32 Professor Dr. Angela M. Kaindl, Charité – Universitätsmedizin Berlin, Campus Virchow-  
33 Klinikum, Augustenburger Platz 1, 13353 Berlin. Tel / Fax: +49 30 450 566301 /7566301.  
34 Email: [angela.kaindl@charite.de](mailto:angela.kaindl@charite.de)\*

35 Professor Fumio Nakamura, Tokyo Women's Medical University, Department of  
36 Biochemistry, 8-1 Kawada-cho, Sinjuku-ku, Tokyo, Japan. 162-8666 Tel / Fax: +81-3-5269-  
37 7415. Email: [nakamura.fumio@twmu.ac.jp](mailto:nakamura.fumio@twmu.ac.jp)\*\*.

38 Dr. Hao Hu, Laboratory of Medical Systems Biology, Guangzhou Women and Children's  
39 Medical Center, Guangzhou Medical University, 9 Jinsui Road, 510623, Guangzhou, China.  
40 Tel / Fax: +86 (0)20 38076326/265. Email: [huh@cougarlab.org](mailto:huh@cougarlab.org)\*\*.

41

42 **Running title:** CRMP1 and neurodevelopmental disorder

43

44 **Keywords:** CRMP1; brain development; intellectual disability; autism spectrum disorder;  
45 neurodevelopmental disorder.

46 **Email addresses:** ethiraj.ravindran@charite.de, arashiki.nobuto@twmu.ac.jp, lena-  
47 luise.becker@charite.de, takizawa.kohtaro@twmu.ac.jp, jonathan.levy@aphp.fr,  
48 thomas.rambaud@laboratoire-sequoia.fr, konstantin.makridis@charite.de,  
49 goshima@yokohama-cu.ac.jp, lina@cougarlab.org, m.vreeburg@mumc.nl,  
50 demeer.benedicte@chu-amiens.fr, adickma@gwdg.de, sander.stegmann@mumc.nl,  
51 huh@cougarlab.org, nakamura.fumio@twmu.ac.jp, angela.kaindl@charite.de

52

53 **Abstract**

54 Collapsing response mediator proteins (CRMPs) are key for brain development and function.  
55 Here, we link CRMP1 to a neurodevelopmental disorder. We report heterozygous *de novo*  
56 variants in the *CRMP1* gene in three unrelated individuals with muscular hypotonia,  
57 intellectual disability and/or autism spectrum disorder. Based on *in silico* analysis these  
58 variants are predicted to affect the CRMP1 structure. We further analyzed the effect of the  
59 variants on the protein structure/levels and cellular processes. We showed that the human  
60 *CRMP1* variants are dominant-negative and impact the oligomerization of CRMP1 proteins.  
61 Moreover, overexpression of mutant-*CRMP1* variants affect neurite outgrowth of murine  
62 cortical neurons. While altered CRMP1 levels have been reported in psychiatric diseases,  
63 genetic mutation in *CRMP1* gene has never been linked to human disease. We report for the  
64 first-time mutations in the *CRMP1* gene and emphasize its key role in brain development and  
65 function by linking directly to a human neurodevelopmental disease.

## 66 **Introduction**

67 Neurodevelopment is a fine-tuned process orchestrated by distinct expression and function of  
68 several genes and any disturbances in this timely-controlled process culminate in  
69 neurodevelopmental disorder.<sup>1,2</sup> Collapsin response mediator proteins (CRMP) are cytosolic  
70 phosphoproteins that are highly and differentially expressed in the nervous system.<sup>3,4</sup> The five  
71 CRMP subtypes (CRMP1-5) form homo- or hetero-tetramers in various combinations and  
72 thereby enable distinct functions key for neurodevelopment.<sup>5</sup> Targeted neurodevelopmental  
73 processes include cell migration, axonal outgrowth, dendritic branching, apoptosis mediated  
74 through extracellular signaling molecules (Sema3A, reelin, neurotrophins).<sup>6-10</sup> CRMP  
75 function is regulated in a spatiotemporal manner through protein phosphorylation mediated by  
76 various kinases such as Cdk5, Rho/ROCK, and GSK3.<sup>11,12</sup>

77 Given their key function in developmental processes, disturbances in CRMP function can  
78 result in neurodevelopmental diseases (NDD). In this line, monoallelic *CRMP5* variants can  
79 cause Ritscher-Schinzel syndrome 4 (MIM#619435), a neurodevelopmental disease with  
80 craniofacial features, cerebral and cardiovascular malformations, and cognitive dysfunction.<sup>13</sup>  
81 *CRMP4* variants have been associated with amyotrophic lateral sclerosis in the French  
82 population.<sup>14</sup>

83 Here, we link for the first time *CRMP1* variants in three unrelated pedigrees to  
84 neurodevelopmental disorder in humans with muscular hypotonia, autism spectrum disorder  
85 (ASD) and/or intellectual disability. In humans, maternal CRMP1 autoantibodies have been  
86 associated with autism in their children, and increased *CRMP1* mRNA levels were identified  
87 in individuals with schizophrenia, attention deficit hyperactivity disorder and ASD.<sup>15,16</sup>  
88 Knockout of *Crmp1* in mice results in schizophrenia-associated behavior, impaired learning  
89 and memory, and prepulse inhibition.<sup>17</sup> On a cellular level, abnormal neurite outgrowth,  
90 dendritic development and orientation, and spine maturation of cortical and/or hippocampal  
91 neurons have been shown.<sup>7-9</sup> Loss of *Crmp* affects long-term potentiation maintenance.<sup>9</sup> In

92 addition, cerebellar development and its loss leads to reduced granule cell proliferation,  
93 apoptosis, and migration in the cerebellum of *Crmp1*<sup>-/-</sup> mice.<sup>10</sup> Although evidence on altered  
94 levels of CRMP1 in neuropsychiatric diseases exists, the mutations in the *CRMP1* gene has  
95 not been linked to a human disease.

## 96 **Subjects and methods**

97 Written informed consent was obtained from all parents of the patients to participate in this  
98 study and publish the data of this research work. The human study adhered to the World  
99 Health Association Declaration of Helsinki (2013) and was approved by the local ethics  
100 committees of the Charité (approval no. EA1/212/08). All animal experimental protocols were  
101 checked and approved by the Institutional Animal Care and Use Committee of the Tokyo  
102 Women's medical University with protocol No. 'AE21-086'. All animal experiments were  
103 performed at daytime. The study was not pre-registered.

104 **Genetic analyses.** In family 1, DNA samples of family members were isolated from  
105 peripheral blood lymphocytes, and whole exome sequencing (WES) was performed on a  
106 HiSeq XTen Deep Sequencer (Illumina, CA, USA), with an average coverage of ~36X,  
107 according to the manufacturer's instructions. The primary data analysis was done by a  
108 combination of Burrows-Wheeler Alignment (BWA) sequence aligner for reads alignment to  
109 human reference genome GRCh37/hg19, Genome Analysis Toolkit (GATK) pipeline for  
110 calling single-nucleotide variant (SNV), and small insertion and deletion (indel), and  
111 ANNOVAR for variant characterization<sup>18-20</sup>. Identified variants were filtered through  
112 comparison with the disease-associated variants in the known databases (Human Gene  
113 Mutation Database (HGMD, 2020.2) and the Online Mendelian Inheritance in Man (OMIM))  
114 and polymorphism databases (dbSNP143, 1000 Genome). Sanger sequencing of the *CRMP1*  
115 gene (NM\_001014809) was performed to confirm the identified variants in the patients and  
116 further family members and performed segregation analysis of the variants with the  
117 phenotype.

118 In family 2, variants were detected by routine WES diagnostics and variant calling using a  
119 parent-offspring trio approach as described previously<sup>21</sup>. Briefly, the exome was captured  
120 using the Agilent SureSelectXT Human All Exon v5 library prep kit (Agilent Technologies,

121 Santa Clara, CA, USA). Exome libraries were sequenced on an Illumina HiSeq 4000  
122 instrument (Illumina, San Diego, CA, USA) with 101 bp paired-end reads at a median  
123 coverage of 75× at the BGI Europe facilities (BGI, Copenhagen, Denmark). Sequence reads  
124 were aligned to the hg19 reference genome using Burrows-Wheeler Alignment (BWA) and  
125 variants were subsequently called by the Genome Analysis Toolkit (GATK) unified  
126 genotyper, version 3.2-2 and annotated using a custom built diagnostic annotation pipeline.  
127 Multi-species sequence alignment were performed using Multialin, PhyloP and PhastCons  
128 and the variants disease- causative nature were predicted using the free online tool Mutation  
129 Taster ([www.mutationtaster.org](http://www.mutationtaster.org)).

130 In family 3, trio-based whole-genome sequencing was performed on blood-derived genomic  
131 DNA at the Laboratoire de biologie médicale multisites SeqOIA (LBMS SeqOIA, Paris,  
132 France). After extraction, DNA samples were sonicated, and libraries were prepared using the  
133 NEBNext Ultra-II kit (New England Biolabs). Whole-genome sequencing was performed in  
134 paired-end 2x150-bp mode, with a NovaSeq6000 (Illumina). Demultiplexed data were aligned  
135 to the genomic reference (hg19). Recalibration and variant calling was performed using  
136 GATK4 (Broad Institute). Short variants were annotated with SNPeff (4.3t). Copy Number  
137 Variants >4kb were called using CNVnator (v0.4.1) and annotated with AnnotSV (v2.5.1).  
138 An average depth-of-coverage of >50x was obtained for both probands, and variants were  
139 prioritized according to impact, frequency, and segregation. Sanger sequencing was  
140 performed to confirm the identified mutation in the *CRMP1* gene.

141 **Expression and purification of recombinant *hCRMP1* variants.** Subcloned GST-tagged  
142 *CRMP1B-V5* expression plasmids (wildtype, P475L, T313M) were transformed into *E. coli*  
143 BL21 (DE3) pLysS cells (BioDynamics Laboratory, Tokyo, Japan). These bacteria were  
144 harvested to 200 ml Terrific Broth medium (Invitrogen, Waltham, MA, USA) including 100  
145 mg/ml ampicillin (Sigma, St. Louis, MO, USA). After incubation for 1.5 h at 37 °C, the



146 protein production was induced by 0.1 mM isopropyl  $\beta$ -D-1-thiogalactopyranoside (Sigma)  
147 for 18 h at 20 °C. Collected bacteria by centrifugation were suspended in 24 ml  
148 homogenization buffer (H buffer; 50 mM Tris/HCl (pH 8.0), 100 mM KCl, 1 mM EDTA, 5%  
149 glycerol, 1% NP-40, 1 mM DTT) and then sonicated 4 times for 5 min on ice using Ultrasonic  
150 Homogenizer (Microtec Co., LTD., Chiba, Japan). After centrifugation at 12,000 rpm for 30  
151 min at 4 °C, resultant supernatants were mixed with 400  $\mu$ l of Glutathione Sepharose 4FF  
152 resin (Cytiva, Tokyo, Japan) and gently inverted for 24 h at 4 °C. The resins were collected  
153 and washed 4 times with 10 ml H buffer, and then washed 5 times with 1 ml cleavage buffer  
154 (C buffer; 20 mM Tris/HCl (pH 8.0), 150 mM NaCl, 0.1% NP-40, 1 mM DTT). The pelleted  
155 resins were suspended in 100  $\mu$ l of C buffer including 10 U PreScission protease (Cytiva) and  
156 incubated for 24 h at 4 °C with constant agitation. These mixtures were transferred to the filter  
157 cups (Vivaclear Mini 0.8  $\mu$ m PES; Sartorius, Stonehouse, UK), and the flow through fractions  
158 were obtained by centrifugation at 10,000 rpm for 1 min at 4 °C. Protein concentrations were  
159 determined using the Bradford reagent (ThermoFisher scientific, Waltham, MA, USA), and  
160 the purified mutants were assessed by SDS-PAGE.

161 **Determination of dominant-negative effect of the CRMP1 variants on the multimer**  
162 **formation of the wild type.** HEK293T cells were co-transfected with pc3.1beta2-V5-  
163 *CRMP1B*-wildtype and either one of myc-tagged *CRMP1B* constructs (wildtype, P475L or  
164 T313M). After 24h incubation, the cells were harvested by modified C buffer (20 mM  
165 Tris/HCl (pH 8.0), 150 mM NaCl, 1% NP-40, 1 mM DTT, protease inhibitor cocktail  
166 (cOmplete mini; Roche)), sonicated for 15 min, and centrifuged at 15,000 rpm for 30 min at 4  
167 °C. Electrophoresis of the resultant supernatants under the native and denaturing state were  
168 performed as described above. Semi-dry Western transfers were carried out at 15 V for 60  
169 min using the transfer buffer, 50 mM Tris, 40 mM glycine, 20% methanol, 0.1% SDS. In the  
170 case of the BN-PAGE, the transferred membranes were incubated in 8% acetic acid for 15

171 min, washed by ultrapure water, and then dried completely, followed by decolorization using  
172 100% methanol. After blocking by 5% skim milk in TBS-T (20 mM Tris/HCl (pH 7.4), 150  
173 mM NaCl, 0.1% Tween-20) for 60 min, the membranes were reacted with anti-myc (9E10)  
174 mAb (1:2,000, FUJIFILM, Cat No. 011-21874) or anti-V5 mAb (1:10,000, Invitrogen  
175 (R960–25) RRID: AB\_2556564) for overnight at 4 °C. Infrared-fluorescence- (IRDye 680RT;  
176 LI-COR, Lincoln, NE, USA) or HRP-conjugated (Dako, Santa Clara, CA, USA) secondary  
177 antibodies were utilized for the detection of the first antibodies on the membranes obtained  
178 from the native or denatured electrophoresis, respectively.

179 **Transfection to primary cultured mouse embryonic cortical neurons.** Pregnant ICR  
180 (RRID:IMSR\_TAC:icr) female mice were purchased from Nihon SLC (Shizuoka, Japan).  
181 Overdose isoflurane (7 - 8%)/air mixture was inhaled to euthanize the pregnant ICR mice  
182 until the loss of breathing. The E15-16 mouse embryos dissected from the pregnant mice were  
183 immediately placed in ice-cold PBS and euthanized by decapitation. Cortices dissected from  
184 the embryos were treated with 1% trypsin/PBS at 37 °C for 5 min and quenched with the  
185 addition of 0.5% trypsin inhibitor. The dissociated neurons were centrifuged at 800 xg for 5  
186 min at 4 °C, washed once, and suspended in DMEM-10% FBS. The cells ( $1.0 \times 10^6$ ) were  
187 transfected with 10 µg of pc3.1beta2-V5 harboring *CRMP1B*-wildtype, -P475L, or -T313M or  
188 using an electroporation equipment NEPA21 (NEPA GENE, Chiba, Japan). The condition of  
189 electroporation was follows: Poring pulse (275 V, 0.5 ms pulse length, 50 ms pulse interval,  
190 10% decay, +pulse orientation, 2 times); Transfer pulse (20 V, 50 ms pulse length, 50 ms  
191 pulse interval, 40% decay, ±pulse orientation, 5 times). The cells were suspended in DMEM-  
192 10% FCS and seeded ( $1 \times 10^4$ /well) on a 24 well culture-plate coated with 0.05 mg/ml of  
193 poly-l-lysine (Wako, Cat No. 163-19091). After overnight incubation, the medium was  
194 replaced with Neurobasal medium supplemented with 2% B-27, 2 mM Glutamax, 50 U/ml  
195 penicillin, and 50 µg/ml streptomycin (500 µl/well) and incubated 37 °C for 6–7 days.

196 **Immunocytochemistry of mice cortical cultured neurons.** The primary cultured cortical  
197 neurons were fixed with 4% paraformaldehyde (PFA)/PBS for 30 min at 25 °C, replaced with  
198 PBS, and stored at 4 °C. As the expression of *V5-CRMP1B* constructs was limited, tyramide  
199 signal amplification (TSA) system (PerkinElmer, Cat No. NEL700A001KT) was applied for  
200 the detection of V5 signal. Briefly, the cells were treated with PBS containing 0.3% H<sub>2</sub>O<sub>2</sub> for  
201 20 min at 25 °C and blocked with 1:1 mixture of PBS supplemented with 0.1% Triton X-100  
202 (PBST) containing 10% skim milk and Tris-buffered serine supplemented with 0.1% Triton  
203 X-100 (TBST) containing 5% normal goat serum (NGS) for 30 min at 25 °C. The cells were  
204 washed twice with TBST and incubated with the primary antibody mixture consisting of  
205 TBST 2.5% NGS, anti-V5 mouse mAb (1:5000) and anti-MAP2 rabbit pAb (1:5000, Covance  
206 (PRB-547C) RRID: AB\_2565455) for overnight at 4 °C. The cells were sequentially  
207 incubated each for 1h at 25°C with TBST 2.5% NGS containing biotin-conjugated anti-mouse  
208 secondary antibody (1:3000, Jackson) and TBST 2.5% NGS containing streptavidin-HRP  
209 conjugate (1/500, dilution, PerkinElmer). Then the cells were reacted with tyramide signal  
210 amplification mixture for 10min at 25°C and subsequently incubated with TBST 2.5% NGS  
211 containing streptavidin-Alexa594 (1:2000) and anti-rabbit secondary antibody-Alexa488 for 2  
212 h at 25 °C. The images of immunostained neurons were captured by an Olympus IX70  
213 microscope equipped with x10 Objective lens and DP74 camera. The neurite outgrowth of  
214 V5- or tdTomato- positive neurons was scored with Fiji software (2.0.0-rc-59/1.51n). In each  
215 condition, 13 to 20 V5- or tdTomato-positive neurons were analyzed.

## 216 **Results**

### 217 **Phenotype and genotype of index patients**

218 Proband 1 (P1) was born as the second child of non-consanguineous healthy parents of  
219 Caucasian descent after an uneventful pregnancy (**Fig 1A, Table 1**). At delivery a singular  
220 umbilical artery was noted. The global development was delayed from infancy on: with sitting  
221 at 1.5-2 years-of-age, standing with support at 1-1.5 years-of-age, walking at 2-2.5 years-of-  
222 age, first words at 2-2.5 years-of-age. Standardized cognitive tests performed at 5-10 years  
223 revealed a moderate intellectual disability with an intelligence quotient (IQ) of 55 at last  
224 assessment using the Kaufman Assessment battery for children (K-ABC). She had speech  
225 disorder. Behavioral problems included a lack of distance to men and a sexualized behavior.  
226 At last assessment at 15-16 years-of-age, the girl had generalized muscular hypotonia with  
227 normal reflexes, but fine motor problems with a broad-based gait but no ataxia. When  
228 climbing stairs, she showed clear instability. The results of cranial magnetic resonance  
229 imaging (MRI) at 1.5 - 4 years as well as that of further work-up (including metabolic tests,  
230 electroencephalogram (EEG), ophthalmological assessment, electrocardiogram,  
231 echocardiogram, abdominal sonography) were normal. Since preliminary genetic tests  
232 including chromosome analysis and array-CGH were normal in the index patient (P1), we  
233 performed whole exome sequencing (WES) to identify the underlying genetic cause. WES  
234 followed by bioinformatic analysis and confirmation with Sanger sequencing revealed the  
235 heterozygous *de novo* variant in the *CRMP1* gene c.1766C>T (NM\_001014809.2; Chr4  
236 (GRCh37):g.5830253G>A) in the affected child P1 (**Fig 1B**). At the protein level, this variant  
237 leads to an amino acid change at position 589 from proline to leucine: P589L in long isoform,  
238 CRMP1A (NP\_001014809.1) and P475L in short form, CRMP1B (NP\_001304.1) (**Fig 1B**).  
239 The identified variant was not found in 1000Genomes, dbSNP or gnomAD. The CADD score  
240 (<https://cadd.gs.washington.edu/>) was 24.5. The mutation localizes to a highly conserved  
241 position, as demonstrated by PhyloP (5.327), PhastCons (1) score and multi-species sequence

242 alignment (**Fig 1C**). The Provean score of the identified variants predicted to have a  
243 deleterious effect (-5.854, cutoff= -2.5).

244 Proband 2 (P2) was born as the second child of non-consanguineous parents of Caucasian  
245 descent after an uneventful pregnancy and delivery (**Fig 1A, Table 1**). The boy was  
246 macrosomic at birth but had no congenital microcephaly. His motor development was delayed  
247 (unsupported walking at 2-2.5 years-of-age) due to congenital mild muscular hypotonia with  
248 normal deep tendon reflexes, but no coordination problems. He had bilateral pes planus. A  
249 speech delay and language impairment with first words spoken at 3-3.5 years-of-age were  
250 diagnosed. He was also diagnosed with an autism spectrum disorder and normal cognitive  
251 abilities (IQ 95). At last assessment at 10-11 years-of-age, an obesity associated with  
252 hyperphagia was of raising concern, and he had secondary enuresis nocturna. The results of a  
253 cranial MRI and EEG were normal. Similarly, through WES followed by bioinformatic  
254 analysis, we identified a heterozygous *de novo* variant c.1280C>T in the *CRMP1* gene  
255 (NM\_001014809.2; Chr4 (GRCh37):g.5841279G>A) in proband (P2) (**Fig 1B**). This variant  
256 leads to an exchange of threonine to methionine at position 427 in the long form, CRMP1A  
257 (p.T427M, NP\_001014809.1) and at position 313 in the short form, CRMP1B (p.T313M,  
258 NP\_001304.1) (**Fig 1B**). The variant affects a highly conserved region of the protein (**Fig**  
259 **1C**).

260 Proband 3 (P3) is the first child of three of a non-consanguineous family of European  
261 descent (**Fig 1A, Table 1**). She was born at gestation week 40 after an uneventful pregnancy,  
262 with normal birth parameters (weight: 3.610 kg, height: 50 cm, head circumference: 32.5cm,  
263 Apgar score: 10/10). She had developmental delay with not being able to sit alone at 1-1.5  
264 years-of-age and walked without support at 2-2.5 years-of-age. Her speech development was  
265 delayed with few words spoken at 2.5-3 years-of-age. She began to gain weight from 1.5-2  
266 years-of-age, and overgrowth was noticed since the 2-2.5 years-of-age. Endocrinological  
267 screening, including leptin blood level was normal. There is familial history of obesity on

268 both parental sides, and one of the parent is macrocephalic. She developed severe behavioral  
269 issues with temper tantrums, stubbornness, hyperphagia, obsessive-compulsive characteristics  
270 and autism spectrum disorder. She was attending medical-educational institute at the age of 8-  
271 8.5 years. At the last assessment of 13-14 years-of-age, she had moderate intellectual  
272 disability and persistent severe behavioral disorders. Distinctive facial features were low  
273 forehead hair insertion, anteverted and large earlobes, broad nasal tip, short philtrum and full  
274 lower lips. Genu valgum and hyperlordosis as well as abdominal and dorsal stretch marks were  
275 noted. Enuresia was noted. Cerebral MRI and abdomino-renal ultrasound were normal.  
276 Metabolics and storage disease screening were negative. Array analysis revealed two  
277 maternally inherited deletions: a 668 kb deletion at 3q26.31 and a 371kb at 5q23.1, confirmed  
278 by genome sequencing and considered as variant of unknown significance. Further analysis  
279 through trio-based whole-genome sequencing identified a *de novo* variant in the *CRMP1* gene  
280 c.1052T>C (NM\_001014809.2; Chr4 (GRCh37):g.5841409A>G) (**Fig 1B**). The identified  
281 variant leads to an exchange of phenyl alanine to serine at position 351 of long form of  
282 CRMP1 (CRMP1A (NP\_001014809.1)) and at position 237 in short form (CRMP1B  
283 (NP\_001304.1)) and it is located in the highly conserved region of the protein (**Fig 1C**). This  
284 variant is not found in gnomAD database. *In silico* pathogenicity prediction tools predicts the  
285 identified variants to be deleterious (CADD pared: 23.60; REVEL 0.577 (Thresholds > 0.5  
286 Damaging), ClinPred 0.975 (Damaging  $\geq$  0.5), Mistic: 0.90 (Damaging Threshold  $\geq$  0.5)). No  
287 additional pathogenic variants have been identified by trio genome sequencing, including all  
288 known genes involved in neurodevelopmental disorder.

### 289 **Effect of identified *CRMP1* variants on protein structure**

290 Since CRMP1 is known to oligomerize to form homotetramers and heterotetramers along  
291 with other CRMPs to regulate cellular functions, we determined the effect of the identified  
292 human variants on its protein structure using known structures and protein structure prediction

293 tools. The structure of CRMP1 short form, CRMP1B, has been determined at 3.05Å  
294 resolution<sup>22</sup> lacking the N-terminal 14 residues and residues 491-572 in their C-terminal  
295 region. CRMP1 monomer consists of three structural parts, N-terminal  $\beta$ -strands followed by  
296 a linker  $\beta$ -strand connected to the central  $\alpha/\beta$ -barrel (**Fig 1D**). Several residues contribute to  
297 the oligomerization interface of CRMP1 and the quaternary structure of CRMP1 tetramer is  
298 shown in **Fig 1E**. The amino acid exchange of P475L, T313M, and F237S are located in the  
299 highly conserved region of CRMP1. The P475L is the last residue before the start of the C-  
300 terminal helix and the exchange of proline to leucine is predicted to lead to serious clashes  
301 with the neighboring residues (**Fig 1F**). Such spatial constraints may alter the dipole moment  
302 of the helix and lead to long-range allosteric effects (**Fig 1G**). The T313M lies within the  
303 region of the  $\alpha/\beta$ -barrel, is oriented towards the inside of the protein and located close to the  
304 ligand-binding active site/cavities (**Fig 1H**). Rearrangements within the protein upon  
305 interaction with other CRMPs or molecules could shuffle these cavities for normal  
306 functioning. The exchange of threonine to methionine is predicted to prevent rearrangements  
307 and to affect the oligomerization as well as other interactions. The F237S is localized directly  
308 in the center of interface 1 so the exchange of a heavy hydrophobic sidechain by a hydrophilic  
309 short sidechain most likely interferes with the stability of the dimer interaction (**Fig 1I**). Based  
310 on structural simulations, all three variants are predicted to affect the ternary structure of  
311 CRMP1 and impact on its oligomerization.

### 312 **P475L and T313M mutations affect homo-oligomerization of CRMP1B**

313 To analyze the effect of *CRMP1* variants on its protein levels and cellular function, two  
314 variants (CRMP1B-P475L (P1) or -T313M (P2)) were chosen for further functional analysis.  
315 We purified the recombinant human CRMP1B-wildtype, -P475L (P1) or -T313M (P2)  
316 proteins using the *E. coli* GST-tag expression system. CRMP1B-wildtype showed two major  
317 64 kDa and 60 kDa bands on SDS-denatured gel electrophoresis (**Fig 2A, left lane**). The 64

318 kDa and 60 kDa correspond to full-length CRMP1B and to a truncated, C-terminal region  
319 cleaved form, respectively. The yield of purified T313M (TM) or P475L (PL) was less than  
320 that of wildtype in the same condition (**Fig 2A, middle and right lanes**). This finding may be  
321 due to lower expression and/or aggregation of the mutant proteins in *E. coli*. As T313M and  
322 P475L mutated residues are positioned close to the dimer/tetramer interface of CRMP1B,  
323 these mutations may affect homo-oligomerization of CRMP1. We therefore examined the  
324 oligomerization of recombinant CRMP1 preparation with Blue-Native gel electrophoresis  
325 (**Fig 2B**). A broad band of CRMP1B-wildtype was present at high (720 kDa) but residual  
326 amount of monomeric form was detected at low molecular weight (70 kDa) on Blue-Native  
327 gel. The 720 kDa band probably represents the homo-oligomerization of CRMP1B-wildtype  
328 under the native condition. In contrast, CRMP1B-T313M and -P475L showed the increased  
329 monomeric 70 kDa band, suggesting weakened self-association of these mutants.

330 As these mutations were found in the heterozygous state in the affected patients, CRMP1B-  
331 T313M and/or -P475L expression might perturb the oligomerization of CRMP1B-wildtype in  
332 a dominant-negative manner. We therefore next co-expressed V5-CRMP1B-wildtype together  
333 with either myc-CRMP1B-wildtype, -T313M, or -P475L in HEK293T cells. As shown in **Fig**  
334 **2C** upper and middle panels, co-expression of myc-CRMP1B-T313M or -P475L did not alter  
335 the expression level of V5-CRMP1B-wildtype on SDS-denatured gel electrophoresis. Anti-  
336 V5 immunoblot analysis of these specimens on Blue-Native gel electrophoresis (**Fig 2C,**  
337 lower panel) revealed that the co-expression of myc-CRMP1B-wildtype showed major 1100  
338 kDa and minor 360 kDa bands of V5-CRMP1-wildtype. In contrast, co-expression of myc-  
339 CRMP1B-T313M or -P475L increased the lower (360 kDa) V5-CRMP1B-wildtype,  
340 suggesting that these mutants potentially impede multimer formation of CRMP1B-wildtype.  
341 As V5-immunoreactive signal at higher molecular size (1100 kDa) in P475L was remarkably  
342 decreased than that in T313M, P475L may exhibit stronger dominant negative effect.



343 **P475L and T313M mutations attenuate neurite outgrowth of cortical neurons**

344 We next asked whether the ectopic expression of *CRMP1B* mutants in primary cultured  
345 murine cortical neurons affect the neuronal development. Dissociated E15 mouse cortical  
346 neurons were electroporated with the expression vector harboring either V5-*CRMP1B*-  
347 wildtype (wt), -T313M (TM), -P475L (PL), or tdTomato. The cells were seeded onto PLL-  
348 coated culture dishes and grown for 6-7 days. After fixation, the cells were immunostained  
349 with anti-V5 and anti-MAP2 antibodies. We found that the longest primary neurites of V5-  
350 *CRMP1B*-T313M or -P475L transfected neurons were shorter than those of V5-*CRMP1B*-  
351 wildtype (wt) or tdTomato transfected cells (**Fig 3A-D**). We then measured the length of the  
352 longest primary neurite from V5- or tdTomato-positive neurons in each condition. The longest  
353 primary neurites expressing *CRMP1B*-T313M or -P475L were 40-50% shorter than those  
354 expressing *CRMP1B*-wildtype (wt) (**Fig 3E**). As the longest primary neurites of the cultured  
355 cortical neurons is thought to be axons, these *CRMP1B* mutants may interfere with the  
356 oligomerization of CRMP1 in turn to attenuate the outgrowth of the cortical axons.

## 357 **Discussion**

358 In this study, we report the human phenotype associated with heterozygous *CRMP1* variants  
359 in three affected children of unrelated non-consanguineous pedigrees. All the patients have a  
360 neurodevelopmental disorder with motor delay and muscular hypotonia. While patient P1 has  
361 moderate intellectual disability and behavioral abnormalities, P2 was diagnosed with an  
362 autism spectrum disorder but a normal cognitive profile and P3 presented with moderate  
363 intellectual disability and autism spectrum disorder.

364 We showed that those human *CRMP1* variants have a dominant-negative effect and impact  
365 the oligomerization of CRMP1 proteins. CRMP1 exists as homo- or hetero-tetramers to  
366 interact with various signaling molecules and to link microtubules to subcellular structures  
367 and regulate cytoskeletal dynamics.<sup>5,23</sup> In line with this, CRMP1 colocalizes to the mitotic  
368 spindles and centrosomes, indicating of playing a key role in mitosis and cell cycle  
369 progression.<sup>24</sup> Defective cell cycle, abnormal mitotic spindle and centrosomes are the  
370 common key pathomechanism underlying several neurodevelopmental disorders.<sup>25</sup>

371 Dysregulation of other CRMPs that have been linked to human disease has been shown to  
372 affect specific cellular processes associated with the clinical phenotype. For example, mutant  
373 CRMP5 impedes the ternary complex formation with microtubule-associated protein 2  
374 (MAP2) and beta-III-tubulin, thereby causing a defective inhibitory regulation on neurite  
375 outgrowth and dendritic development and thereby contribute to the brain malformation  
376 phenotype.<sup>13</sup> MAP2 has been already reported to play a key role in neurite outgrowth and  
377 synaptic plasticity through its role in microtubule stabilization and cytoskeletal  
378 association.<sup>26,27</sup> Also, mutant CRMP4 was shown to affect axonal growth and survival of  
379 motor neurons and thereby contribute to the amyotrophic lateral sclerosis phenotype.<sup>14</sup> In this  
380 study we showed that the identified *CRMP1* variants affect neurite outgrowth, which is a  
381 characteristic phenotype associated to many neurodevelopmental/psychiatric disorders.<sup>28</sup> Our  
382 finding is in line with the reduced neurite outgrowth phenotype and impaired long-term

383 potentiation in the *Crmp1*<sup>-/-</sup> mice.<sup>9</sup> Mechanistically, these cellular processes are regulated in a  
384 spatiotemporal manner through CRMP1 phosphorylation by several kinases such as Cdk5,  
385 Rho/ROCK or GSK3, and any disturbances in these kinases or mutation of specific residues  
386 culminates in the abnormal brain development.<sup>6,8-11,29</sup> In the case of *Cdk5*<sup>-/-</sup> mice, abnormal  
387 dendritic spine morphology was shown in cortical neurons as it was in *Crmp1*<sup>-/-</sup> mice.  
388 Intriguingly, both mouse models show schizophrenia-like behavior, indicating the commonly  
389 shared cellular mechanism for dendritic development.<sup>9,30</sup> In the context of neuronal  
390 development, defective phosphorylation of tyrosine residues in CRMP1 by Fyn-mediated  
391 Reelin signaling impairs cortical neuron migration.<sup>6</sup> Over the last two decades, new  
392 phosphorylation specific sites in CRMP1 are being reported and recently, phosphorylation of  
393 Tyr504 residue by Fyn has been shown to play an important step in Sema3A-regulated  
394 dendritic development of cortical neurons.<sup>31</sup> As a future perspective, it will be interesting to  
395 find other *CRMP1* variants and elucidate the role of specific residues in various neuronal  
396 process and associate with the phenotypic spectrum of neurodevelopmental disorder.

397 In conclusion, we report for the first time human *CRMP1* mutations, link them to a human  
398 neurodevelopmental disease and highlight underlying pathomechanisms. Our report adds  
399 *CRMP1* to list of other *CRMP* genes linked to neurological disorders and underlines the  
400 important role of CRMP1 in the nervous system development and function.

401 **Declaration of interest**

402 The authors declare no competing interests.

403

404 **Data availability**

405 All methods applied in this project are described in detail in the ‘Materials and  
406 Methods’ section and the original data are presented as source file

407

408 **Acknowledgements**

409 The authors thank the index families for their participation in this study. We acknowledge  
410 Petra Bittigau, Akosua Sarpong for attending the patients; Anna Tietze for the analysis of  
411 cranial MR images; Sabrina Pommer and Jessica Fassbender for technical assistance; Piotr  
412 Neumann for assistance in data interpretation and lively discussions; Dr. Tanabe Kenji and  
413 Dr. Fumitoshi Saitoh for electroporation equipment. We acknowledge the funding resources  
414 for this study: German Research Foundation (SFB665, SFB1315, FOR3004, AMK), the  
415 Sonnenfeld Stiftung (AMK, KLM), the Berlin Institute of Health (BIH, CRG1, AMK), the  
416 Charité (AMK, ER, LLB, KLM), and by grants-in-aid for Scientific Research from the Japan  
417 Society for the Promotion of Science (JSPS) (16K07062) (FN).

## 418 References

- 419 1. Rice D, Barone S, Jr. Critical periods of vulnerability for the developing nervous  
420 system: evidence from humans and animal models. *Environ Health Perspect.* Jun 2000;108  
421 Suppl 3:511-33. doi:10.1289/ehp.00108s3511
- 422 2. Gilbert SL, Dobyns WB, Lahn BT. Genetic links between brain development and  
423 brain evolution. *Nat Rev Genet.* Jul 2005;6(7):581-590. doi:10.1038/nrg1634
- 424 3. Strittmatter L-HWaSM. A Family of Rat CRMP Genes Is Differentially Expressed in  
425 the Nervous System. *J Neurosci* 1996;16:6197–6207
- 426 4. Bretin S, Reibel S, Charrier E, et al. Differential expression of CRMP1, CRMP2A,  
427 CRMP2B, and CRMP5 in axons or dendrites of distinct neurons in the mouse brain. *J Comp*  
428 *Neurol.* May 23 2005;486(1):1-17. doi:10.1002/cne.20465
- 429 5. Wang LH, Strittmatter SM. Brain CRMP forms heterotetramers similar to liver  
430 dihydropyrimidinase. *J Neurochem.* Dec 1997;69(6):2261-9. doi:10.1046/j.1471-  
431 4159.1997.69062261.x
- 432 6. Yamashita N, Uchida Y, Ohshima T, et al. Collapsin response mediator protein 1  
433 mediates reelin signaling in cortical neuronal migration. *J Neurosci.* Dec 20  
434 2006;26(51):13357-62. doi:10.1523/JNEUROSCI.4276-06.2006
- 435 7. Naoya Yamashita AM, Yutaka Uchida, Fumio Nakamura, Hiroshi Usui, Toshio  
436 Ohshima, Masahiko Taniguchi, Jérôme Honnorat, Nicole Thomasset, Kohtaro Takei, Takuya  
437 Takahashi, Pappachan Kolattukudy, Yoshio Goshima. Regulation of spine development by  
438 semaphorin3A through cyclin-dependent kinase 5 phosphorylation of collapsin response  
439 mediator protein 1. *J Neurosci*  
440 2007 (Nov 14;27(46):12546-54)
- 441 8. Hiroko Makihara SN, Wataru Ohkubo, Naoya Yamashita, Fumio Nakamura, Hiroshi  
442 Kiyonari , Go Shioi , Aoi Jitsuki-Takahashi , Haruko Nakamura, Fumiaki Tanaka , Tomoko  
443 Akase, Pappachan Kolattukudy , Yoshio Goshima CRMP1 and CRMP2 have synergistic but  
444 distinct roles in dendritic development. *Genes Cells.* 2016;Sep;21(9):994-1005.
- 445 9. Su KY, Chien WL, Fu WM, et al. Mice deficient in collapsin response mediator  
446 protein-1 exhibit impaired long-term potentiation and impaired spatial learning and memory.  
447 *J Neurosci.* Mar 7 2007;27(10):2513-24. doi:10.1523/JNEUROSCI.4497-06.2007
- 448 10. Charrier E, Mosinger B, Meissirel C, et al. Transient alterations in granule cell  
449 proliferation, apoptosis and migration in postnatal developing cerebellum of CRMP1-/- mice.  
450 *Genes Cells.* Dec 2006;11(12):1337-52. doi:10.1111/j.1365-2443.2006.01024.x
- 451 11. Yutaka Uchida TO, Yukio Sasaki,Hiromi Suzuki,Shigeki Yanai,Naoya  
452 Yamashita,Fumio Nakamura,Kohtaro Takei,Yasuo Ihara,Katsuhiko Mikoshiba,Papachan  
453 Kolattukudy,Jerome Honnorat,Yoshio Goshima. Semaphorin3A signalling is mediated via  
454 sequential Cdk5 and GSK3 $\beta$  phosphorylation of CRMP2: implication of common  
455 phosphorylating mechanism underlying axon guidance and Alzheimer's disease. *Genes to*  
456 *Cells* 2005;(10,165– 179)
- 457 12. Yoshimura T, Kawano Y, Arimura N, et al. GSK-3beta regulates phosphorylation of  
458 CRMP-2 and neuronal polarity. *Cell.* Jan 14 2005;120(1):137-49.  
459 doi:10.1016/j.cell.2004.11.012
- 460 13. Jeanne M, Demory H, Moutal A, et al. Missense variants in DPYSL5 cause a  
461 neurodevelopmental disorder with corpus callosum agenesis and cerebellar abnormalities. *Am*  
462 *J Hum Genet.* May 6 2021;108(5):951-961. doi:10.1016/j.ajhg.2021.04.004
- 463 14. Blasco H, Bernard-Marissal N, Vourc'h P, et al. A rare motor neuron deleterious  
464 missense mutation in the DPYSL3 (CRMP4) gene is associated with ALS. *Hum Mutat.* Jul  
465 2013;34(7):953-60. doi:10.1002/humu.22329

- 466 15. Braunschweig D, Krakowiak P, Duncanson P, et al. Autism-specific maternal  
467 autoantibodies recognize critical proteins in developing brain. *Transl Psychiatry*. Jul 9  
468 2013;3:e277. doi:10.1038/tp.2013.50
- 469 16. Bader V, Tomppo L, Trossbach SV, et al. Proteomic, genomic and translational  
470 approaches identify CRMP1 for a role in schizophrenia and its underlying traits. *Hum Mol*  
471 *Genet*. Oct 15 2012;21(20):4406-18. doi:10.1093/hmg/dds273
- 472 17. Naoya Yamashita AT, Keizo Takao, Toshifumi Yamamoto, Pappachan Kolattukudy,  
473 Tsuyoshi Miyakawa, Yoshio Goshima. Mice lacking collapsin response mediator protein 1  
474 manifest hyperactivity, impaired learning and memory, and impaired prepulse inhibition.  
475 *Front Behav Neurosci*. 2013 (Dec 27;7:216.)
- 476 18. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler  
477 transform. *Bioinformatics*. Mar 1 2010;26(5):589-95. doi:10.1093/bioinformatics/btp698
- 478 19. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants  
479 from high-throughput sequencing data. *Nucleic Acids Res*. Sep 2010;38(16):e164.  
480 doi:10.1093/nar/gkq603
- 481 20. Mark A DePristo EB, Ryan Poplin, Kiran V Garimella, Jared R Maguire, Christopher  
482 Hartl, Anthony A Philippakis, Guillermo del Angel, Manuel A Rivas, Matt Hanna, Aaron  
483 McKenna, Tim J Fennell, Andrew M Kernysky, Andrey Y Sivachenko, Kristian Cibulskis,  
484 Stacey B Gabriel, David Altshuler & Mark J Daly A framework for variation discovery and  
485 genotyping using next-generation DNA sequencing data. *Nature Genetics*. 2011;(43,  
486 pages491–498 (2011))
- 487 21. de Ligt J, Willemssen MH, van Bon BW, et al. Diagnostic exome sequencing in  
488 persons with severe intellectual disability. *N Engl J Med*. Nov 15 2012;367(20):1921-9.  
489 doi:10.1056/NEJMoa1206524
- 490 22. Liu SH, Huang SF, Hsu YL, et al. Structure of human collapsin response mediator  
491 protein 1: a possible role of its C-terminal tail. *Acta Crystallogr F Struct Biol Commun*. Aug  
492 2015;71(Pt 8):938-45. doi:10.1107/S2053230X15009243
- 493 23. Nakamura F, Kumeta K, Hida T, et al. Amino- and carboxyl-terminal domains of  
494 Filamin-A interact with CRMP1 to mediate Sema3A signalling. *Nat Commun*. Oct 31  
495 2014;5:5325. doi:10.1038/ncomms6325
- 496 24. Shih JY, Lee YC, Yang SC, et al. Collapsin response mediator protein-1: a novel  
497 invasion-suppressor gene. *Clin Exp Metastasis*. 2003;20(1):69-76.  
498 doi:10.1023/a:1022598604565
- 499 25. Zaqout S, Kaindl AM. Autosomal Recessive Primary Microcephaly: Not Just a Small  
500 Brain. *Front Cell Dev Biol*. 2021;9:784700. doi:10.3389/fcell.2021.784700
- 501 26. Kaech S, Parmar H, Roelandse M, Bornmann C, Matus A. Cytoskeletal  
502 microdifferentiation: a mechanism for organizing morphological plasticity in dendrites. *Proc*  
503 *Natl Acad Sci U S A*. Jun 19 2001;98(13):7086-92. doi:10.1073/pnas.111146798
- 504 27. Sanchez C, Diaz-Nido J, Avila J. Phosphorylation of microtubule-associated protein 2  
505 (MAP2) and its relevance for the regulation of the neuronal cytoskeleton function. *Prog*  
506 *Neurobiol*. Jun 2000;61(2):133-68. doi:10.1016/s0301-0082(99)00046-5
- 507 28. Prem S, Millionig JH, DiCicco-Bloom E. Dysregulation of Neurite Outgrowth and Cell  
508 Migration in Autism and Other Neurodevelopmental Disorders. *Adv Neurobiol*. 2020;25:109-  
509 153. doi:10.1007/978-3-030-45493-7\_5
- 510 29. Yamashita N, Goshima Y. Collapsin response mediator proteins regulate neuronal  
511 development and plasticity by switching their phosphorylation status. *Mol Neurobiol*. Apr  
512 2012;45(2):234-46. doi:10.1007/s12035-012-8242-4
- 513 30. Yamashita N, Takahashi A, Takao K, et al. Mice lacking collapsin response mediator  
514 protein 1 manifest hyperactivity, impaired learning and memory, and impaired prepulse  
515 inhibition. *Front Behav Neurosci*. 2013;7:216. doi:10.3389/fnbeh.2013.00216

516 31. Kawashima T, Jitsuki-Takahashi A, Takizawa K, et al. Phosphorylation of Collapsin  
517 Response Mediator Protein 1 (CRMP1) at Tyrosine 504 residue regulates Semaphorin 3A-  
518 induced cortical dendritic growth. *J Neurochem.* May 2021;157(4):1207-1221.  
519 doi:10.1111/jnc.15304

520 **Table 1: Phenotype of patients with *CRMP1* variants.**

521

<b>Characteristics and Symptoms</b>	<b>Proband 1 (Pedigree I)</b>	<b>Proband 2 (Pedigree II)</b>	<b>Proband 3 (Pedigree III)</b>
<i>CRMP1</i> variant (NM_001014809.2); (NP_001014809.1)	c.1766C>T; p.P589L	c.1280C>T; p.T427M	c.1052T>C; p.F351S
Parents	non-consanguineous	non-consanguineous	non-consanguineous
Gender	female	male	female
Anthropometric data	normal	normal	Overgrowth
weight (kg)	57.1 (0.15 SD)	N/A	133 (14.2 SD)
height (cm)	168 (0.43 SD)		166.5 ( 2.94 SD)
OFC (cm)	53.5 (-1.02 SD)		62 (5 SD)
Pregnancy, birth, postnatal adaption	normal	normal	normal
singular umbilical artery	+	-	-
macrosomia	-	+	-
fetal fingerpads	-	+	-
Microcephaly (OFC < -2 SD)	-	-	-
Macrocephaly (OFC > -2 SD)	-	-	+ (5 SD )
Facial dysmorphism	-	-	+
Delayed motor development	+	+	+
walking unsupported (years)	2-2.5	2-2.5	2-2.5
Global muscular hypotonia	mild	mild	mild
Deep tendon reflexes	normal	normal	normal
Intellectual disability	moderate (IQ 55)	no (IQ 95)	moderate
Autism spectrum disorder	-	+	-
Behavioral problems			
lack of distance, sexualized behavior	+	+	+
hyperphagia	+	-	-
	-	+	+
Delayed speech and language development (first words spoken) (years)	+	+	+
	(2-2.5)	(3-3.5)	(3-3.5)
Fine motor problems	+	-	+
Other			
secondary enuresis nocturna	-	+	+
pes planus	-	+	-
obesity	-	+	+
EEG results	normal	normal	normal
Cranial MRI abnormalities	-	-	-

522 +, yes; -, no; IQ, intellectual quotient; N/A, not available; OFC, occipitofrontal  
523 circumference; SD, standard deviation.



524 **Figure Legends:**

525 **Fig 1: Genotype of patients with variants in *CRMP1*.** **A.** Pedigree of index families. **B.**  
526 Pictogram representing the CRMP1 cDNA with identified variant of proband 1 (P1) in exon  
527 12 (c.1766C>T, NM\_001014809.2) which leads on protein level to an amino acid change of  
528 proline to leucine in CRMP1 (CRMP1A-long form (p.P589L, NP\_001014809.1) and  
529 CRMP1B-short form (p.P475L, NP\_001304.1)); the variant in proband 2 (P2) in exon 9  
530 c.1280C>T (NM\_001014809.2) leads to an exchange of threonine to methionine (CRMP1A  
531 (p.T427M, NP\_001014809.1) and CRMP1B (p.T313M, NP\_001304.1)); the variant in  
532 proband 3 (P3) in exon 6 c.1052T>C (NM\_001014809.2) leads to an exchange of phenyl  
533 alanine to serine (CRMP1A (p.F351S, NP\_001014809.1) and CRMP1B (p.F237S,  
534 NP\_001304.1)). **C.** Multi-species sequence alignment localizes the variants in the highly  
535 conserved area of CRMP1. **D.** The short form CRMP1 monomer is composed of three  
536 structural parts, an N-terminally located 7  $\beta$ -strands forming two  $\beta$ -sheets (depicted in blue),  
537 followed by a linker  $\beta$ -strand (yellow) connecting to the central  $\alpha/\beta$ -barrel (cyan/magenta)  
538 formed by 7 repeats. Inserted after repeat 4 are 2 additional  $\alpha$ -helices (gray) **E.** CRMP1  
539 assembles into tetramers. The relevant sites of mutation T313M, P475L and F237S are  
540 indicated as sphere model, with the T313 and F237 located in the central channel in the  
541 vicinity of the interaction sites and P475L is located at the beginning of the C-terminal helix  
542 and oriented towards the adjacent molecules. **F.** The mutation P475L reveals serious clashes  
543 with neighboring residues (red hexagonals) which may be accounted for by a shift of the helix  
544 as shown in **(G)**. **H.** Detailed representation of the structural vicinity of the T313M (yellow)  
545 to the ligand-binding cavity (magenta). **I.** Magnified view of interface 1 tilted 90 ° backwards  
546 complex with respect to panel E highlighting the arrangement of the two phenylalanines at  
547 position 237 from the neighboring units. The exchange of phenylalanine with hydrophobic

548 residues to serine with hydrophilic side chain interferes with the stability of the interaction in  
549 interface 1.

550 **Fig 2. Attenuated oligomer formation of CRMP1-P475L and CRMP1B-T313M mutants.**

551 **A.** Purified CRMP1B-wildtype, -T313M, and -P475L recombinant proteins on SDS- PAGE  
552 stained with CBB. GST-tagged CRMP1 were expressed in *E. coli* and purified through the  
553 binding to glutathione resin and the digestion with PreScission protease. Equal volume (2.5  
554  $\mu$ l) of the purified specimens, which were prepared in the same condition, were loaded on the  
555 gel. The yield of the mutants was less than that of CRMP1-wildtype as shown in panel. Two  
556 major 64 kDa and 60 kDa bands in the preparations are full-length and truncated form,  
557 respectively. **B.** Estimation of the multimeric state under native condition. Bacterially  
558 expressed and purified CRMP1B specimens (5 g) were electrophoresed on NativePAGE  
559 Novex 4-16% Bis-Tris gel in the presence of CBB-G250. The gel was stained with CBB-  
560 R250 to visualize separated proteins. CRMP1B-wildtype exhibited major 720 kDa and minor  
561 70 kDa bands, which respectively represent homo-oligomer and monomer. In contrast,  
562 CRMP1B-T313M and -P475L showed predominant 70 kDa bands, suggesting that the  
563 mutations may interfere with the homo-oligomerization of CRMP1. **C.** Dominant negative  
564 effect of T313M and P475L mutant on the oligomerization of CRMP1B-wildtype. HEK293T  
565 cells co-expressing V5-CRMP1B-wildtype and either one of myc-CRMP1B-wildtype, -  
566 T313M, or -P475L were analyzed. Anti-V5 and anti-myc immunoblot analyses of the  
567 specimens subjected to SDS-PAGE showed that the expression level of V5-CRMP1 and myc-  
568 CRMP1 in each condition was similar extent (upper and middle panels). Anti-V5 immunoblot  
569 analysis of these specimens on Blue-Native gel electrophoresis is shown (lower panel). Co-  
570 expression of V5-CRMP1B-wildtype and myc-CRMP1B-wildtype exhibited major 1100 kDa  
571 and minor 360 kDa V5-reactive bands. In contrast, co-expression of myc-CRMP1B-T313M  
572 or -P475L increased the lower (360 kDa) V5-reactive band. This suggests that co-expression

573 of these mutants may interfere with multimer formation of V5-CRMP1B-wildtype.

574 Abbreviations: CRMP1B-wildtype, wt; CRMP1B-T313M, TM; CRMP1B-P475L, PL

575 **Fig 3. Attenuated neurite outgrowth by the ectopic expression of CRMP1B- P475L and**

576 **CRMP1B-T313M mutants. A-D.** Representative images of the neurons expressing V5-

577 CRMP1B-wildtype (A), -T313M (B), -P475L (C), or tdTomato (D). Transfected neurons

578 were visualized by anti-V5 immunostaining or tdTomato expression (red) and anti-MAP2

579 immunostaining (green). The longest primary neurites of the neurons expressing V5-

580 CRMP1B-T313M or -P475L were shorter than those of the neurons transfected with V5-

581 CRMP1B-wildtype or tdTomato. Scale bars, 100  $\mu$ m. **E.** Longest primary neurite length. The

582 length of the longest primary neurite from V5- or tdTomato-positive neurons was scored in

583 each condition. The graph represents average  $\pm$  SEM with individual values from four

584 independent experiments. The number of examined neurons in each condition is CRMP1B-

585 wildtype, 66; -T313M, 64; -P475L, 49; tdTomato, 73. Data were analyzed by one-way

586 ANOVA followed by Tukey's post-hoc test. **\*\*** $p < .01$ , **\*\*\*** $p < 0.001$ .

587 **Author contributions.** AMK and FN were responsible for project conception. AMK, MV,  
588 BD analyzed and interpreted patient's clinical data. LLB and KLM contributed clinical  
589 information by gathering clinical information and written informed consents. HH, NL, APAS,  
590 JL, TR performed WES and bioinformatics data analysis. ER performed Sanger sequencing  
591 and segregation analysis. NA, KT and FN performed functional experiments. AD performed  
592 structural prediction analysis. ER and AMK drafted the manuscript that was revised and  
593 accepted by all coauthors.





